|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The effect of PAI-1 upon angiogenesis is also involved in atherosclerosis, in which high levels of PAI-1 expression are observed.
|
17509745 |
2007 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Increased expression of plasminogen activator inhibitor-1 (PAI-1) mRNA in atherosclerotic human arteries suggests a linkage between PAI-1 gene expression and cellular proliferation, the fundamental feature of atherosclerosis.
|
9108786 |
1997 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These results suggests that hyperhomocysteinemia-induced atherosclerosis and/or thrombosis may be caused by homocysteine-induced stimulation of PAI-1 gene expression and secretion in the vasculatures by a mechanism independent from paracrine-autocrine activity of TGFbeta and TNFalpha.
|
10872824 |
2000 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this patient, without traditional risk factors for atherosclerosis, eight mutations and polymorphisms in six different genes were identified: polymorphism of factor V Leiden (1691 GA), factor II prothrombin (20210 GA), methylenetetrahydrofolate reductase (MTHFR, 677 CT and 1298 AC), plasminogen activator inhibitor 1 (PAI-1) polymorphism 4G/5G and glycoprotein VI (GP6, 13254 TC, Ser219Pro).
|
28382527 |
2017 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
We tested the hypothesis that leptin induces PAI-1 and inhibits tPA expression using human coronary artery endothelial cells (HCAEC) in culture as these cells play an important role in atherosclerosis.
|
20051227 |
2010 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
The aim of this cross-sectional study was to evaluate the differences in plasma levels of plasminogen activator inhibitor-1 (PAI-1) and of von Willebrand factor (vWF) as endothelial hemostatic markers and carotid intima-media thickness (C-IMT) as a morphologic marker for atherosclerotic vascular disease among dyslipidemic individuals with apoB levels higher, estimated or lower based on regression equation of apoB vs non-HDL-C.
|
28502501 |
2018 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Common variation of the DNA sequence in the promoter region, such as that occurring in the human apolipoprotein A-I and plasminogen activator inhibitor(-1) genes, may account for subtle differences in serum lipid levels and risk of atherosclerotic vascular disease in the general population.
|
8743897 |
1996 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
The levels of CLOCK, leukemia inhibitory factor (LIF), intercellular adhesion molecule 1 (ICAM-1), perilipin 2 (ADFP), nuclear factor kappa B (NF-κB), and plasminogen activator inhibitor-1 (PAI-1), as well as the number of atherosclerotic plaques were elevated in the AS mouse model, as compared with the control group.
|
30124738 |
2018 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
LHGDN |
Studies with transgenic mice have revealed a functional role for PAI-1 in wound healing, atherosclerosis, metabolic disturbances such as obesity and insulin resistance, tumor angiogenesis, chronic stress, bone remodeling, asthma, rheumatoid arthritis, fibrosis, glomerulonephritis and sepsis.
|
15634264 |
2005 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
PAI-1 has been linked to fibrin deposition that evolves into organ fibrosis and atherosclerosis.
|
28785222 |
2017 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Its effects on ROS production, AP-1 activity, plasminogen activator inhibitor 1 (PAI-1) gene expression, and cellular proliferation and migration were measured in response to high glucose and angiotensin II (Ang II) concentrations, two major factors in the pathogenesis of atherosclerosis in patients with diabetes and hypertension.
|
15827742 |
2005 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In this study we explored the microRNAs responsible for the regulation of PAI-1 during LPS-stimulated inflammation in human aortic endothelial cells and subsequently studied the effect of a newly synthesized mitochondria-targeted esculetin (Mito-Esc) that was shown for its anti-atherosclerotic potential, in modulating PAI-1 levels and its targeted miRs during angiotensin-II-induced atherosclerosis in ApoE<sup>-/-</sup> mice.
|
28213977 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
LHGDN |
Elevated plasma PAI-1 activity was independently associated with coronary microvascular dysfunction, which suggests that plasma PAI-1 activity is an important clue linking hypofibrinolysis to the development of atherosclerosis.
|
17322633 |
2007 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
Endothelial dysfunction in patients suffering from atherosclerosis or diabetes type 2 is associated not only with suppression in release of the above mediators but also with deleterious discharge of prostaglandin endoperoxides (PGH2, PGG2), superoxide anion (O2-, peroxynitrite (ONOO-), and plasminogen activator inhibitor (PAI-1).
|
11208485 |
2001 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
One of the well-known physiological substances that induce the PAI-1 gene is tumor necrosis factor-alpha, which also induces other possible risk factors of atherosclerosis, intercellular adhesion molecule-1 (ICAM-1) and vascular cell adhesion molecule-1.
|
9187938 |
1997 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Fibrinogen, factor VII and PAI-1 genotypes and the risk of coronary and peripheral atherosclerosis: Edinburgh Artery Study.
|
10235438 |
1999 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Plasma PAI-1 levels and 4G/4G genotype frequency were significantly higher in the severe atheromatosis group compared to the other groups (p<0.001).
|
22011808 |
2011 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to investigate the effect of tPA (tissue plasminogen activator) and PAI-1 (plasminogen activator inhibitor) antigen concentrations and 4G/5G polymorphism of the PAI-1 gene on the development of atherosclerosis in SLE patients.
|
21719525 |
2011 |
|
Atherosclerosis
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Therefore, we performed this study to better assess the relationship between PAI-1 genetic variations and atherosclerosis.
|
29908999 |
2018 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In conclusion, obesity and TNF-alpha up-regulation of PAI-1 expression in human hepatocytes may contribute to the impairment of the fibrinolytic system, leading to the development of atherosclerosis and liver fibrosis in insulin-resistant individuals.
|
17046548 |
2006 |
|
Atherosclerosis
|
0.400 |
Biomarker
|
disease |
BEFREE |
We demonstrated that the increase of sICAM-1, sVCAM-1 and PAI-1, together with decrease of omentin-1 led to a proinflammatory imbalance pointing to the presence of subclinical atherosclerosis, and improving CVD risk stratification in non-smoking patients at early stage MetS beyond traditional scores.
|
31349950 |
2019 |
|
Atherosclerosis
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
Since NF-kappaB-mediated gene products, such as fibrinogen and PAI-1, are known to facilitate hypercoagulation, thrombosis and vascular events, we suggest that nilvadipine has a direct beneficial effect separate from its anti-hypertensive properties by inhibiting NF-kappaB-dependent gene expression and eventually inhibiting atherosclerosis.
|
15530472 |
2004 |